News | Stem Cell Therapies | February 01, 2019

Heart Muscle Cells Created From Stem Cells Beat in Sync

New study shows how newly created cardiac muscle cells can be made to pump together

Heart Muscle Cells Created From Stem Cells Beat in Sync

February 1, 2019 — A team of Rutgers scientists have taken an important step toward the goal of making diseased hearts heal themselves – a new model that would reduce the need for bypass surgery, heart transplants or artificial pumping devices.

The study, recently published in Frontiers in Cell and Developmental Biology,1 involved removing connective tissue cells from a human heart, reverse-engineering them into heart stem cells, then re-engineering them into heart muscle cells.

The Rutgers team’s true breakthrough, however, is that the newly created cardiac muscle cells clumped together into a single unit that visibly pumps under the microscope.

Senior author Leonard Y. Lee, chair of the Department of Surgery at Rutgers Robert Wood Johnson Medical School, said cardiac cells made in this way do not normally come together and beat as one. His team succeeded in making this happen by over-expressing, a protein in the cells called CREG.

According to Lee, fibroblasts, a cell in connective tissue, were isolated from the heart tissue and reverse-engineered – or transformed – into stem cells.  This was done so that when the CREG protein was over-expressed the stem cells would differentiate into cardiac cells.

Heart failure has reached epidemic proportions. Right now, the only option to treat it is surgery, transplant or connecting the patient with a blood-pumping machine,” Lee said. “But transplantable hearts are in short supply and mechanical devices limit the patient’s quality of life. So, we are working for ways to help hearts heal themselves.”

Though still far off, Lee’s ultimate goal is to be able to remove small amounts of a patient’s native heart tissue, use CREG to convert the tissue into cardiac muscles that will work together cohesively, and re-introduce them into the patient’s heart allowing it to heal itself.

For more information: www.frontiersin.org/journals/cell-and-developmental-biology

Reference

1. Ghobrial G., Araujo L., Jinwala F., et al. The Structure and Biological Function of CREG. Frontiers in Cell and Developmental Biology, Oct. 26, 2018. https://doi.org/10.3389/fcell.2018.00136

Related Content

American Heart Association Introduces New Post-acute Care Heart Failure Certification
News | Heart Failure | July 03, 2019
The new Post-Acute Care Heart Failure Certification offered from the American Heart Association (AHA) provides...
Novel Therapeutic Approach Effective at Reducing Pressure for Heart Failure Patients

Image courtesy of Kapur N.K., Karas R.H., Burkhoff D., et al.

News | Heart Failure | June 17, 2019
Results from a first-in-man proof of concept study found occlusion of the superior vena cava (SVC) rapidly and...
Tafamidis meglumine (Vyndaqel) is one of two new drugs cleared by the FDA for the treatment of the cardiomyopathy caused by transthyretin mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM. U.S. Food and Drug Administration (FDA) approved tafamidis meglumine (Vyndaqel) and tafamidis (Vyndamax) capsules for the treatment of the cardiomyopathy.

Tafamidis meglumine (Vyndaqel) is one of two new drugs cleared by the FDA for the treatment of the cardiomyopathy caused by transthyretin mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM. 

Technology | Heart Failure | May 06, 2019
May 6, 2019 — The U.S.
The Aortic intra-aortic axial flow pump is designed to unload the heart and increase renal perfusion in heart failure patients experiencing cardiorenal syndrome.

The Aortic intra-aortic axial flow pump is designed to unload the heart and increase renal perfusion in heart failure patients experiencing cardiorenal syndrome.

Feature | Heart Failure | April 29, 2019 | Will Clifton, M.D.
The heart and kidneys are inextricably linked through a diverse web of hemodynamic, neural and hormonal mechanisms.
Diabetes Drug May Reverse Heart Failure
News | Heart Failure | April 19, 2019
Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated that the recently developed antidiabetic...
Diabetes Drug Effective Against Heart Failure in Wide Spectrum of Patients
News | Heart Failure | March 29, 2019
The cardiovascular benefits of the diabetes drug dapagliflozin extend across a wide spectrum of patients and are...
New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril/valsartan (Entresto) continued to deliver reductions in the heart failure biomarker N-terminal pro–B-type natriuretic peptide (NT-proBNP), an established biomarker for heart failure severity and prognosis.[1] The data was presented as a late-breaker at the American College of Cardiology (ACC) 2019 Annual Scientific Session in March.
News | Heart Failure | March 27, 2019
March 27, 2019 —New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril/valsa
Toilet Seat Detects Congestive Heart Failure

Nicholas Conn, a postdoctoral fellow at RIT and founder and CEO of Heart Health Intelligence, is part of the university team that has developed a toilet-seat based cardiovascular monitoring system. Image courtesy of A. Sue Weisler/RIT.

News | Heart Failure | March 26, 2019
March 26, 2019 — A toilet seat-based ...
FDA Approves Optimizer Smart System for Heart Failure Patients offers cardiac contractility modulation.
Technology | Heart Failure | March 21, 2019
The U.S. Food and Drug Administration (FDA) approved Impulse Dynamics’ Optimizer Smart system for treating patients...
Overlay Init